Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia - Wikidata - wikimedia - TriplyDB

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

http://www.wikidata.org/entity/Q55966607

about

Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia Demographics, guidelines, and clinical experience in severe community-acquired pneumonia Community acquired bacterial pneumonia Interventions to improve antibiotic prescribing practices for hospital inpatients Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections Combating antimicrobial resistance: policy recommendations to save lives Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis Duration of antimicrobial therapy in community acquired pneumonia: less is more Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections Biomarkers in community-acquired pneumonia: a state-of-the-art review Tools for outcome prediction in patients with community acquired pneumonia.Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.Procalcitonin for clinical decisions on influenza-like illness in emergency department during influenza a(H1N1)2009 pandemic.Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia.Revolutionizing clinical microbiology laboratory organization in hospitals with in situ point-of-care Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia.Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study Using Procalcitonin to Guide Antibiotic Therapy.Association of adrenal function and disease severity in community-acquired pneumonia.Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome.Predicting treatment failure in severe sepsis and septic shock: looking for the Holy Grail Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention St Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial Defining and predicting severe community-acquired pneumonia.Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients.Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection.Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

P2860

Q21194921-B00ED32E-D6F1-43AC-BD7A-74CE235251C3 Q21195015-C7DB85DD-D4EE-4C2C-9446-73C546609CBB Q22241379-5F0D7267-0F33-4890-A8DC-11E0E9D33E28 Q24197807-9D959460-E0A9-438D-AB7C-F460F68594D2 Q24200676-8B04317D-F7DB-4607-8D17-125E1C0B5715 Q24241768-35C8DEBA-517C-46D9-B869-CC19DC827602 Q24632857-A4245ADB-2DAB-4FC2-BE02-08A9E1E51619 Q26782662-BD7935DE-EC31-4855-8950-DDFEFBABB265 Q26798459-D576716D-006D-4DC9-8607-2D6DEBD626F6 Q26799899-330409AB-89C6-4F96-94C9-4AA5C45F8B65 Q26827765-AA19AA8E-0BD8-4F88-9D01-58ACF84BEEE4 Q26828493-85A75FD4-8ADF-4E3C-ADB4-982A6D600062 Q27023057-51A1FE64-7EF5-49AB-B1A1-C7990F0A31BF Q27026995-9118C050-5C63-4C92-8EDC-2AE9CA69E314 Q30240254-C9D97251-5B15-43C5-BD78-8CA5C691DF43 Q30360003-7F5D282D-14D7-4062-83F9-1D20ABC9EAF6 Q30396773-6ADA471E-ACA1-473C-BD35-5C1FFDA5E9D5 Q30403782-1E19DCA1-A925-4F44-937D-03DFBF13F0A3 Q31029164-4E96D194-6E03-47BE-9813-7112F5201DFA Q33276665-D917FCC2-28C8-4EC8-B17B-7EA010F77277 Q33290142-C177068A-EA4A-4510-9253-CED7AA2FEEA7 Q33321452-0619F6C9-881E-4403-809C-EDDBFC6B910A Q33400876-D724FD53-F408-487E-9C53-E69DAD6954FA Q33505806-0923125B-3316-4009-9F9D-36180BC8CEE3 Q33520362-1B418DDC-40E7-4142-938F-4B2D1EFEBB64 Q33540012-53928E2D-72FE-479F-928C-83CFBDE93D29 Q33629533-E5F4D5C2-F136-4F83-B820-AB946CD303A5 Q33629591-A1E226B9-602B-44E6-9FB0-2423499817CB Q33728018-CE75B4B3-D5C1-4844-8D7B-0584794707E5 Q33749972-F990707C-F26C-4648-A19F-12E490B9A559 Q33753353-B067CA7C-0010-4169-B020-45CA1E5E633C Q33766905-DB32FCF6-0EE5-4F5C-9D3D-486326CE14B3 Q33827245-6D7FE419-9C80-4520-A40D-9A9D8D4A847B Q33853198-B1737CBD-D753-47F1-A10D-26B09DE0AEEC Q33872274-B46ED076-2925-4F92-A330-C9CFAD5F5FF7 Q33889170-0C38492C-34A8-4129-A7A2-28367E05E094 Q34001903-E1639AFA-C5EE-44AA-B185-CF62F1CBD03A Q34017829-9442F36A-958E-448D-B7AE-099E516AAC33 Q34026905-F70D1156-B6AC-4469-9638-B72F8B372A41 Q34026963-BAC4AEFF-5EA1-4E61-AC85-BD898B0C23B4

P2860

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

http://www.wikidata.org/entity/Q55966607

description

im Juli 2006 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2006

@uk

name

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@en

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@nl

type

label

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@en

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@nl

prefLabel

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@en

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@nl

P1433

Q55966607-8645C64D-6038-4990-8FFA-8D193D6C3ED1

P1476

Q55966607-33DF8856-1D2D-4055-B7AB-28B35170E598

P2093

Q55966607-29FE52A4-148C-401C-A400-C7E3D72CE53B

Q55966607-35685B25-74D0-4480-9933-B094C9B911F2

Q55966607-8CD2EC6C-60D5-4637-BDDC-B4889B153A66

Q55966607-C05B83EA-2E15-4D57-AF7F-6DA7AF5887E8

Q55966607-F23646CB-F919-4617-BE2B-3C0BD3504866

Q55966607-F7DA4046-8EE2-44A4-B71F-EE18B583045F

Q55966607-FE3F0BE1-50B8-45D7-B872-A91071B4374C

P2860

Q55966607-0077C2A5-B8EC-45C0-9AF9-0EED1F11B77A

Q55966607-0096887C-D04D-4A42-A45D-253142196A40

Q55966607-0134B414-7634-4193-A092-27301864F067

Q55966607-0B2B1BB2-DD01-45A7-A1C4-F1FF2C3D6233

Q55966607-0CC53C18-87F8-4E99-BE65-76085FD94688

Q55966607-0D476FFA-EF38-430C-9CDD-9448F2C8AD6F

Q55966607-0DB22BE7-734D-44AF-A819-C4E7EF2AC5C1

Q55966607-1E6CB58A-1F8A-4246-815B-4562B1B54F63

Q55966607-1EA5947D-EB34-4935-B1C9-788FE9642AF1

Q55966607-1F4E759B-0BF4-43E0-B47A-03FC30B62B57

P304

Q55966607-AF478D2B-58E0-4DB2-82B7-1980E149ED23

P31

Q55966607-A4B880D6-58CA-480F-AA5E-C64984A1C792

P356

Q55966607-CAA2D886-3219-47FA-B92A-20C801A67DE7

P407

Q55966607-972FCBB0-5E02-47E0-B54F-7E464CFD301C

P433

Q55966607-CF5C01B7-A0E9-4813-B8E5-A0BC0A76B9FE

P478

Q55966607-97316D1E-7AF6-456D-A942-C264EADB466D

P50

Q55966607-3A3763C4-955C-4F4F-A469-A419527A4CCA

Q55966607-6C62DB15-E9C1-4A72-B84D-3303B913A9A4

Q55966607-6F8DBE7A-423F-48B0-856A-5D6EACA907C9

P577

Q55966607-269F8C7E-7D8C-4FA4-B97A-5204C90D0F8B

P5875

Q55966607-29230096-92C9-4068-B9D3-3639C2643BAC

P698

Q55966607-0B70F3A2-149F-40AC-BFEB-A83031A82088

P921

Q55966607-7E0DEAAE-F913-45EC-833F-9E512A448E89

P356

RCCM.200512-1922OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

@en

P2093

Beat Müller

http://www.w3.org/2001/XMLSchema#string

Christian Müller

http://www.w3.org/2001/XMLSchema#string

Daiana Stolz

http://www.w3.org/2001/XMLSchema#string

David Miedinger

http://www.w3.org/2001/XMLSchema#string

Michael Tamm

http://www.w3.org/2001/XMLSchema#string

Peter R. Huber

http://www.w3.org/2001/XMLSchema#string

Werner Zimmerli

http://www.w3.org/2001/XMLSchema#string

P2860

Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN731826

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

Pneumonia in the very old

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

A prediction rule to identify low-risk patients with community-acquired pneumonia

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials.

Toward a consensus definition for COPD exacerbations.

Clinical practice. Management of community-acquired pneumonia.

Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.

P304

84-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200512-1922OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P50

Roland Bingisser

Mirjam Christ-Crain

Stephan Harbarth

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7175565

http://www.w3.org/2001/XMLSchema#string

P698

16603606

http://www.w3.org/2001/XMLSchema#string

P921